奈玛特韦与新冠成人住院或死亡风险:基于电子健康记录的目标随机试验模拟
该研究模拟随机目标试验,纳入美国退伍军人事务部数据库中256 288例SARS-CoV-2阳性且有至少一项重症危险因素的成人,比较检测阳性5天内启动奈玛特韦与无治疗在30天住院或死亡风险上的差异。结果显示,无论未接种、接种一或两剂、接种加强针,以及原发感染或再感染,奈玛特韦均与30天住院或死亡风险降低相关。
要点
- 未接种者中奈玛特韦相对风险0.60,绝对风险降低1.83%。
- 接种一或两剂者相对风险0.65,绝对风险降低1.27%。
- 接种加强针者相对风险0.64,绝对风险降低1.05%。
核心结论
- 在有重症风险的SARS-CoV-2感染者中,与无治疗相比,奈玛特韦与30天住院或死亡风险降低相关。
- 该关联在未接种、接种一或两剂、接种加强针者中均观察到。
- 该关联在原发感染和再感染者中均观察到。
研究设计与样本
- 采用电子健康记录模拟随机目标试验。
- 数据来源为美国退伍军人事务部医疗数据库。
- 31 524例在检测阳性5天内接受奈玛特韦治疗,224 764例未治疗。
- 采用逆概率加权平衡组间特征,用加权Kaplan-Meier估计30天累积发病率并计算相对风险和绝对风险降低。
主要发现
- 未接种者(n=76 763)中,奈玛特韦组30天住院或死亡相对风险0.60(95%CI 0.50至0.71),绝对风险降低1.83%(95%CI 1.29%至2.49%)。
- 接种一或两剂者(n=84 620)中,相对风险0.65(95%CI 0.57至0.74),绝对风险降低1.27%(95%CI 0.90%至1.61%)。
- 接种加强针者(n=94 905)中,相对风险0.64(95%CI 0.58至0.71),绝对风险降低1.05%(95%CI 0.85%至1.27%)。
- 原发感染者(n=228 081)中,相对风险0.61(95%CI 0.57至0.65),绝对风险降低1.36%(95%CI 1.19%至1.53%)。
- 再感染者(n=28 207)中,相对风险0.74(95%CI 0.63至0.87),绝对风险降低0.79%(95%CI 0.36%至1.18%)。
关键数值与推荐
- 在≤65岁和>65岁、男性和女性、黑人和白人参与者中,奈玛特韦均与住院或死亡风险降低相关。
- 在具有1-2、3-4和≥5项重症危险因素者中,奈玛特韦均与住院或死亡风险降低相关。
- 在奥密克戎BA.1或BA.2优势期和BA.5优势期感染者中,奈玛特韦均与住院或死亡风险降低相关。
临床怎么用
- 对于有重症风险的SARS-CoV-2感染者,无论疫苗接种状态或既往感染史,可考虑在检测阳性5天内启动奈玛特韦以降低30天住院或死亡风险。
- 临床决策时应结合患者年龄、性别、种族、危险因素数量及流行变异株背景综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the effectiveness of nirmatrelvir, compared with no treatment, in reducing admission to hospital or death at 30 days in people infected with the SARS-CoV-2 virus and at risk of developing severe disease, according to vaccination status and history of previous SARS-CoV-2 infection. DESIGN: Emulation of a randomized target trial with electronic health records. SETTING: Healthcare databases of the US Department of Veterans Affairs PARTICIPANTS: 256 288 participants with a SARS-CoV-2 positive test result and at least one risk factor for developing severe covid-19 disease, between 3 January and 30 November 2022. 31 524 were treated with nirmatrelvir within five days of testing positive for SARS-CoV-2 and 224 764 received no treatment. MAIN OUTCOME MEASURES: The effectiveness of starting nirmatrelvir within five days of a positive SARS-CoV-2 test result versus no treatment in reducing the risk of admission to hospital or death at 30 days was estimated in those who were not vaccinated, in those who received one or two doses of vaccine, and those who received a vaccine booster and, separately, in participants with a primary SARS-CoV-2 infection or reinfection. The inverse probability weighting method was used to balance personal and health characteristics between the groups. Relative risk and absolute risk reduction were computed from cumulative incidence at 30 days, estimated by weighted Kaplan-Meier estimator. RESULTS: Among people who were not vaccinated (n=76 763; 5338 nirmatrelvir and 71 425 no treatment), compared with no treatment, the relative risk of nirmatrelvir in reducing admission to hospital or death at 30 days was 0.60 (95% confidence interval 0.50 to 0.71); the absolute risk reduction was 1.83% (95% confidence interval 1.29% to 2.49%). The relative risk and absolute risk reduction, compared with no treatment, were 0.65 (0.57 to 0.74) and 1.27% (0.90% to 1.61%), respectively, in people who received one or two doses of vaccine (n=84 620; 7989 nirmatrelvir and 76 631 no treatment); 0.64 (0.58 to 0.71) and 1.05% (0.85% to 1.27%) in individuals who received a booster dose of vaccine (n=94 905; 18 197 nirmatrelvir and 76 708 no treatment); 0.61 (0.57 to 0.65) and 1.36% (1.19% to 1.53%) in participants with a primary SARS-CoV-2 infection (n=228 081; 26 350 nirmatrelvir and 201 731 no treatment); and 0.74 (0.63 to 0.87) and 0.79% (0.36% to 1.18%) in participants who were reinfected with the SARS-CoV-2 virus (n=28 207; 5174 nirmatrelvir and 23 033 no treatment). Nirmatrelvir was associated with a reduced risk of admission to hospital or death in those aged ≤65 years and > 65 years; in men and women; in black and white participants; in those with 1-2, 3-4, and ≥5 risk factors for progression to severe covid-19 illness; and in those infected during the omicron BA.1 or BA.2 predominant era, and the BA.5 predominant era. CONCLUSIONS: In people with SARS-CoV-2 infection who were at risk of developing severe disease, compared with no treatment, nirmatrelvir was associated with a reduced risk of admission to hospital or death at 30 days in people who were not vaccinated, vaccinated, and had received a booster vaccine, and in those with a primary SARS-CoV-2 infection and reinfection.
引用
- Xie Y, Bowe B, Al-Aly Z, et al. Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records. BMJ. 2023. PMID: 37041016. doi:10.1136/bmj-2022-073312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。